Skip Navigation



Rheumatology Advance Access published online on October 14, 2009
Rheumatology, doi:10.1093/rheumatology/kep323
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Amital, H.
Right arrow Articles by Shalev, V.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amital, H.
Right arrow Articles by Shalev, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Comment on: Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate: reply

Howard Amital1, Yoav Arnson1, Gabriel Chodick2 and Varda Shalev2

1Department of Medicine ‘D’, Meir Medical Center, Kfar-Saba and 2Department of Medical Informatics, Maccabi Healthcare Services, Israel

Correspondence to: Howard Amital, Department of Medicine ‘D’, Meir Medical Center, Kfar-Saba, Israel. E-mail: howard.amital@clalit.org.il

The first 10% of the full text of this article appears below.

SIR, We thank our colleague for the well-written and interesting comments [1] regarding our study [2]. The differences between the views of dermatologists and rheumatologists regarding prevention of MTX hepatotoxicity are . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?